CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin

CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the tumor microenvironment. Therefore, it is not surpris...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobastova, Liudmila, Lettau, Marcus, Babatz, Felix, de Oliveira, Thais Dolzany, Nguyen, Phuong-Hien, Pauletti, Bianca Alves, Schauss, Astrid C., Dürkop, Horst, Janssen, Ottmar, Paes Leme, Adriana F., Hallek, Michael, Hansen, Hinrich P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362802/
https://www.ncbi.nlm.nih.gov/pubmed/34395429
http://dx.doi.org/10.3389/fcell.2021.698503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362802/
https://www.ncbi.nlm.nih.gov/pubmed/34395429
http://dx.doi.org/10.3389/fcell.2021.698503

Ejemplares similares